Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 152 of the 154 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To formulate clinical practice guidelines for the pharmacological management of obesity. PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. This guideline was co-sponsored by the European Society of Endocrinology and The Obesity Society. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the European Society of Endocrinology, and The Obesity Society reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize some of the supporting evidence. CONCLUSIONS: Weight loss is a pathway to health improvement for patients with obesity-associated risk factors and comorbidities. Medications approved for chronic weight management can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone. Many medications commonly prescribed for diabetes, depression, and other chronic diseases have weight effects, either to promote weight gain or produce weight loss. Knowledgeable prescribing of medications, choosing whenever possible those with favorable weight profiles, can aid in the prevention and management of obesity and thus improve health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In contrast, the National Institute for Health and Clinical Excellence (NICE) [37], Endocrine Society [35], and American College of Cardiology [36] uniformly recommend using only licensed medications for weight management and did not consider off-label options such as metformin.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [35]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The STEP 1, 3, and 4 trials used semaglutide in conjunction with a lifestyle program and resulted in 16.9% to 18.2% weight-loss (using a completers-type analysis), which is superior to phase 3 trial results for other weight-loss medications, though without head-to-head drug comparison.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [759]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Commonly prescribed medications such as antidepressants (eg, mirtazapine, amitriptyline) and antihyperglycemics such as glyburide or insulin cause weight gain, and clinicians should review and consider alternatives.”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consideration of individual food preferences, cultural traditions, and budgetary requirements may aid in the adherence to healthy dietary patterns, a key predictor of success [42,45].”
From Nutritional considerations with antiobesity medications (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medication classes promoting weight gain include antihyperglycemics (eg, glyburide, insulin), antidepressants (eg, amitriptyline, mirtazapine), antipsychotics (eg, olanzapine, quetiapine), antiepileptics (eg, gabapentin, carbamazepine), β-blockers, progesterone-based contraceptives, corticosteroids, and antiretroviral therapy (eg, protease inhibitors).12,77”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“The AHA/ ACC/TOS Guideline for the Management of Overweight and Obesity in Adults reviewed randomized clinical trials on weight loss interventions and determined that the best weight loss outcomes occur with frequent face-to-face visits (16 visits per year on average) (8, 38).”
BackgroundGrading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in the development and implementation of evidence-based guidelines (1).”
MethodOverweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“obese are at increased risk for many malignancies (7).”
BackgroundDecision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 1×
“GLP-1 agonists also affect the POMC neurons and cause satiety (18).”
Background
Research works printed but not linked: 15
- [3]3. DomecqJP,PrutskyG,LeppinA,etal. Drugscommonlyassociated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab . 2015;100:363-370.
- [11]11. Goldsmith R, Joanisse DR, Gallagher D, et al. Effects of experimentalweightperturbationonskeletalmuscleworkefficiency,fuel utilization, and biochemistry in human subjects. Am J Physiol Regul Integr Comp Physiol . 2010;298:R79-R88.
- [19]19. Stahl SM. Impulsivity, compulsivity, and addiction. In: Stahl's Essential Psychopharmacology . 4th ed. New York, NY: Cambridge University Press; 2013:537-575.
- [22]22. Mendieta-ZerónH,LópezM,DiéguezC. Gastrointestinalpeptides controlling body weight homeostasis. Gen Comp Endocrinol . 2008;155:481-495.
- [35]35. Avenell A, Brown TJ, McGee MA, et al. Whatinterventions should weaddtoweightreducingdietsinadultswithobesity?Asystematic review of randomized controlled trials of adding drug therapy, exercise, behaviourtherapyorcombinationsoftheseinterventions. J Hum Nutr Diet . 2004;17:293-316.
- [68]68. Grandy S, Hashemi M, Langkilde AM, Parikh S, Sjöström CD. Changesinweightloss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab . 2014;16:645-650.
- [79]79. Greenway FL, Fujioka K, Plodkonski RA, et al. COR I Study Group. Lancet . 2010;376:595-605.
- [82]82. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weightgainintype 2 diabetes mellitus. Diabetes Obes Metab . 2007;9:386-393.
- [88]88. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain duringinsulintherapywithandwithoutmetformininpatientswith type II diabetes mellitus. Diabetologia . 1999;42:406-412.
- [95]95. WingLM,ReidCM,RyanP,etal. Acomparisonofoutcomeswith angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med . 2003;348:583-592.
- [110]110. MaayanL,CorrellCU. Weightgainandmetabolicrisks associated withantipsychoticmedicationsinchildrenandadolescents. J Child Adolesc Psychopharmacol . 2011;21:517-535.
- [126]126. Boers M, van der Heijde DM. Prevention or retardation of joint damageinrheumatoidarthritis:issuesofdefinition,evaluationand interpretation of plain radiographs. Drugs . 2002;62(12):17171724.
- [128]128. Aronne LJ. Drug-induced weight gain: non-CNS medications. In: Aronne LJ, ed. A Practical Guide to Drug-Induced Weight Gain . Minneapolis, MN: McGraw-Hill; 2002:77-91.
- [14]14. tional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol . 2005;100:1072-1081.
- [146]146. Huang MH, Chen CH, Chen TW, Weng MC, Wang WT, Wang YL. Theeffectsofweightreductionontherehabilitationofpatients with knee osteoarthritis and obesity. Arthritis Care Res . 2000;13: 398-405.
Cited by
Items 201–300 of 1,001
Jirapinyo, P., Hadefi, A., Huberty, V., Sullivan, S. A., Thompson, C. C., Patai, Á. V., Pannala, R., Goelder, S. K., Kushnir, V. M., Barthet, M. A., et al. (2024) · Endoscopy · doi:10.1055/a-2292-2494 · Cited by 78
Self-citationThe cost‐effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity
Lee, M., Lauren, B. N., Zhan, T., Choi, J., Klebanoff, M., Abu Dayyeh, B., Taveras, E. M., Corey, K., Kaplan, L., & Hur, C. (2020) · Obesity Science & Practice · doi:10.1002/osp4.390 · Cited by 61
“In addition, given the widespread off‐label use of phentermine for over 20 years without any evidence of serious side effects, the Endocrine Society includes phentermine in their Clinical Practice Guideline, assuming educated patient preference, response to treatment, and no history of cardiovascular disease or increa…”
BackgroundVillarreal-Calderón, J. R., Cuellar-Támez, R. X., Ramos-González, M. R., Rubio‐Infante, N., Castillo, E. C., Elizondo‐Montemayor, L., & García‐Rivas, G. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/3940739 · Cited by 69
“Several drugs, indicated as a complementary treatment to lifestyle changes, have proven to be effective in achieving a weight loss of 5% [16, 17].”
BackgroundLorenzo, P. M., Sajoux, I., Izquierdo, A. G., Gómez-Arbeláez, D., Zulet, M. Á., Abete, I., Castro, A. I., Baltar, J., Portillo, M. P., Tinahones, F. J., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.05.007 · Cited by 63
Zheng, H., Liu, M., Li, S., Shi, Q., Zhang, S., Zhou, Y., & Su, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.706914 · Cited by 60
“Weight loss medications for obesity include phentermine, topiramate/phentermine, lorcaserin, orlistat, naltrexone/bupropion and liraglutide, often with some side effects for long-term use (6).”
BackgroundWeight loss efficiency and safety of tirzepatide: A Systematic review
Lin, F., Yu, B., Ling, B., Lv, G., Shang, H., Zhao, X., Jie, X., Chen, J., & Li, Y. (2023) · PLOS ONE · doi:10.1371/journal.pone.0285197 · Cited by 60
Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations
Stogios, N., Humber, B. E., Agarwal, S. M., & Hahn, M. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01458-0 · Cited by 64
Implications of a New Obesity Definition Among the All of Us Cohort
Fourman, L. T., Awwad, A., Gutiérrez‐Sacristán, A., Dash, C. A., Johnson, J. E., Thistle, A. K., Chahal, N., Stockman, S. L., Toribio, M. P., Anekwe, C. V., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.37619 · Cited by 72
Simon, R., & Lahiri, S. W. (2018) · Endocrine Practice · doi:10.4158/ep-2017-0221 · Cited by 59
Practical Use of Pharmacotherapy for Obesity
Igel, L. I., Kumar, R. B., Saunders, K. H., & Aronne, L. J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.049 · Cited by 62
Self-citationZhang, Y., Balasooriya, H., Sirisena, S., & Ng, K. (2022) · Food Chemistry · doi:10.1016/j.foodchem.2022.134668 · Cited by 71
Reprint of: Healthy Weight and Obesity Prevention
Lavie, C. J., Laddu, D., Arena, R. A., Ortega, F. B., Alpert, M., & Kushner, R. F. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.024 · Cited by 67
Treatment of Obesity in Mitigating Metabolic Risk
Heffron, S. P., Parham, J. S., Pendse, J., & Alemán, J. O. (2020) · Circulation Research · doi:10.1161/circresaha.119.315897 · Cited by 59
The new era of drug therapy for obesity: the evidence and the expectations
Jones, B. J., & Bloom, S. R. (2015) · Drugs · doi:10.1007/s40265-015-0410-1 · Cited by 58
“Weight loss agents are generally licensed for use in patients with a BMI C30 kg/m(2), or C27–28 kg/ m(2) in those with an obesity-associated comorbidity [102].”
BackgroundWeight management interventions in women with and without PCOS: a systematic review
Kataoka, J., Tassone, E., Misso, M., Joham, A., Stener-Victorin, E., Teede, H., & Moran, L. (2017) · Nutrients · doi:10.3390/nu9090996 · Cited by 58
Savas, M., Muka, T., Wester, V. L., van den Akker, E. L. T., Visser, J. A., Braunstahl, G.-J., Slagter, S. N., Wolffenbuttel, B. H. R., Franco, O. H., & van Rossum, E. F. C. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01133 · Cited by 58
KUTNEY, K. A., Sandouk, Z., Desimone, M. E., & Moheet, A. A. (2021) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2021.100276 · Cited by 79
“Due to increased risk for fat soluble vitamin deficiencies, Orlistat use in people with CF is inadvisable [49].”
BackgroundMethodInfluentialTraish, A. M., & Zitzmann, M. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-015-9323-2 · Cited by 60
“A recent report by the Endocrine Society estimates that more than 78million Americans are obese and more than 11 million are morbidly obese and require surgical intervention to manage their disease [6].”
BackgroundCambi, M. P. C., Baretta, G. A. P., Magro, D. D. O., Boguszewski, C. L., Ribeiro, I. B., Jirapinyo, P., & de Moura, D. T. H. (2021) · Obesity Surgery · doi:10.1007/s11695-020-05164-1 · Cited by 64
Saunders, K. H., Shukla, A. P., Igel, L. I., Kumar, R. B., & Aronne, L. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.04.005 · Cited by 60
“In 2015, the Endocrine Society published clinical practice guidelines on pharmacologic management of obesity.(7) These evidence-based guidelines include recommendations for individualized weight management and ongoing evaluation of medication efficacy.”
BackgroundSelf-citationTHE CONCEPT OF NOVEL NATIONAL CLINICAL GUIDELINES ON OBESITY
Shlyakhto, E. V., Nedogoda, S. V., Конради, А. О., Баранова, Е. И., Fomin, V. V., Vertkin, A. L., & Chumakova, G. A. (2016) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2016-4-7-13 · Cited by 76
Gerngroß, C., Schretter, J., Klingenspor, M., Schwaiger, M., & Fromme, T. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183988 · Cited by 57
Dong, Z., Xu, L., Liu, H., Lv, Y., Zheng, Q., & Li, L. (2017) · Obesity Reviews · doi:10.1111/obr.12606 · Cited by 57
Kim, Y., Austin, S. B., Subramanian, S. V., & Kawachi, I. I. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198841 · Cited by 65
“, eating only bananas for 2–3 weeks) warrants further public health investigation as the current clinical guideline for obesity management recommends the use of mild-to-moderate level caloric restriction without depriving essential nutrients through a balanced diet [33, 59].”
BackgroundMetabolic Surgery for Hypertension in Patients With Obesity
Pareek, M., Bhatt, D. L., Schiavon, C. A., & Schauer, P. R. (2019) · Circulation Research · doi:10.1161/circresaha.118.313320 · Cited by 65
Ketogenic diets as treatment of obesity and type 2 diabetes mellitus
Casanueva, F. F., Castellana, M., Bellido, D., Trimboli, P., Castro, A. I., Sajoux, I., Rodríguez-Carnero, G., Gómez-Arbeláez, D., Crujeiras, A. B., & Olmos, M. Á. M. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09580-7 · Cited by 61
Pharmacotherapies for post-bariatric weight regain: real-world comparative outcomes
Gazda, C. L., Clark, J. D., Lingvay, I., & Almandoz, J. P. (2021) · Obesity · doi:10.1002/oby.23146 · Cited by 56
“Phentermine and other stimulant AOMs are not recommended in the setting of uncontrolled hypertension or cardiovascular disease (10), which are common in people with obesity (30).”
BackgroundInfluentialZhou, J., Ding, L., Chen, W., & Wang, Y. (2023) · Food Frontiers · doi:10.1002/fft2.252 · Cited by 61
Gilden, A. H., Catenacci, V. A., & Taormina, J. M. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202405210 · Cited by 60
Acupuncture and Lifestyle Modification Treatment for Obesity: A Meta-Analysis
Fang, S., Wang, M., Zheng, Y., Zhou, S., & Ji, G. (2017) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x1750015x · Cited by 58
Obesity Treatment with Botulinum Toxin-A Is Not Effective: a Systematic Review and Meta-Analysis
Bustamante, F., Brunaldi, V., Bernardo, W. M., de Moura, D. T. H., Moura, E. T. H. D., Neto, M. G., Santo, M. A., & de Moura, E. G. H. (2017) · Obesity Surgery · doi:10.1007/s11695-017-2857-5 · Cited by 57
Moldovan, C. P., Weldon, A. J., Daher, N. S., Schneider, L. E., Bellinger, D. L., Berk, L. S., Hermé, A. C., Aréchiga, A. L., Davis, W. L., & Peters, W. R. (2016) · Obesity · doi:10.1002/oby.21649 · Cited by 55
“Phentermine is primarily a noradrenergic and possibly dopaminergic sympathomimetic amine that functions as an appetite suppressant (11), and it is the oldest pharmacological agent approved by the United States Food and Drug Administration (FDA) for weight loss (12).”
BackgroundWeight History in Clinical Practice: The State of the Science and Future Directions
Kushner, R. F., Batsis, J. A., Butsch, W. S., Davis, N., Golden, A., Halperin, F., Kidambi, S., Machineni, S., Novick, M., Port, A., et al. (2020) · Obesity · doi:10.1002/oby.22642 · Cited by 55
“For example, if the history suggests a genetic condition or a secondary cause of obesity, appropriate screening should be pursued (32).”
BackgroundRebello, C. J., Nikonova, E. V., Zhou, S., Aronne, L. J., Fujioka, K., Garvey, W. T., Smith, S. R., Coulter, A. A., & Greenway, F. L. (2018) · Obesity · doi:10.1002/oby.22094 · Cited by 55
“Phentermine is primarily a noradrenergic and perhaps dopaminergic sympathomimetic amine that acts as an appetite suppressant (11).”
Self-citationEzzat, S. M., Bishbishy, M. H. E., Aborehab, N. M., Salama, M. M., Hashish, A. F., Motaal, A. A. A., Rashad, H. M., & Metwally, F. M. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112541 · Cited by 69
Maunder, A., Bessell, E., Lauche, R., Adams, J., Sainsbury, A., & Fuller, N. R. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13973 · Cited by 55
Medications for the treatment of obesity in adolescents
Woodard, K., Louque, L., & Hsia, D. S. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820918789 · Cited by 53
Janssen, L. G. M., Nahon, K. J., Bracké, K. F. M., van den Broek, D., Smit, R., Sardjoe Mishre, A. S. D., Koorneef, L. L., Martinez-Tellez, B., Burakiewicz, J., Kan, H. E., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154167 · Cited by 54
Six intragastric balloons: Which to choose?
Stavrou, G., Shrewsbury, A. D., & Kotzampassi, K. E. (2021) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v13.i8.238 · Cited by 63
Gigliotti, L., Warshaw, H., Evert, A., Dawkins, C., Schwartz, J., Susie, C., Kushner, R., Subramanian, S., Handu, D., & Rozga, M. (2025) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2024.10.023 · Cited by 53
Lee, K., Abraham, S., & Cleaver, R. (2022) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2022.07.006 · Cited by 53
Ma, J., Li, C., Wang, J., & Gu, J. (2020) · Obesity · doi:10.1002/oby.22700 · Cited by 55
“It is a major contributor to a variety of chronic diseases, including type 2 diabetes, hypertension, cardiovascular disease, nonalcoholic fatty liver disease, stroke, and osteoarthritis (2-5), with enormous economic burden on both families and society (6,7).”
Background21st Century Advances in Multimodality Imaging of Obesity for Care of the Cardiovascular Patient
Neeland, I. J., Yokoo, T., Leinhard, O. D., & Lavie, C. J. (2021) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2020.02.031 · Cited by 53
Metformin: an old therapy that deserves a new indication for the treatment of obesity.
Igel, L. I., Sinha, A., Saunders, K. H., Apovian, C. M., Vojta, D., & Aronne, L. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0568-3 · Cited by 52
Self-citationCalderon, G., Gonzalez-Izundegui, D., Shan, K. L., Garcia-Valencia, O. A., Cifuentes, L., Campos, A., Collazo-Clavell, M. L., Shah, M., Hurley, D. L., Abu Lebdeh, H. S., et al. (2022) · International Journal of Obesity · doi:10.1038/s41366-021-01019-6 · Cited by 52
Precision medicine in adult and pediatric obesity: a clinical perspective
Bomberg, E. M., Ryder, J. R., Brundage, R. C., Straka, R. J., Fox, C. K., Gross, A. C., Oberle, M. M., Bramante, C. T., Sibley, S. D., & Kelly, A. S. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819863022 · Cited by 52
Hormonal Gut–Brain Signaling for the Treatment of Obesity
Roh, E., & Choi, K. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043384 · Cited by 66
“Pharmacological management of obesity as an adjunct to lifestyle intervention is recommended in people with a BMI ≥30 kg/m2 or 27–30 kg/m2 with at least one obesity-related complication, such as type 2 diabetes, hypertension, dyslipidemia, or sleep apnea [12].”
BackgroundQuarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Quarenghi, R. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113791 · Cited by 67
“In recent years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs, e.g., semaglu-tide) and hybrid gastric inhibitory polypeptide (GIP) analogs and GLP-1 RAs (GIP/GLP-1 RAs, e.g., tirzepatide) have emerged as novel pharmacological agents for the treatment of obesity [15,16].”
van Dammen, L., Wekker, V., de Rooij, S. R., Groen, H., Hoek, A., & Roseboom, T. J. (2018) · Obesity Reviews · doi:10.1111/obr.12752 · Cited by 52
“International guidelines advise lifestyle modification as the first step in treatment of overweight and obesity (13).”
BackgroundA narrative review of approved and emerging anti-obesity medications
Abdi Beshir, S., Ahmed Elnour, A., Soorya, A., Parveen Mohamed, A., Sir Loon Goh, S., Hussain, N., Al Haddad, A. H. I., Hussain, F., Yousif Khidir, I., & Abdelnassir, Z. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101757 · Cited by 51
“More-over, phentermine and diethylpropion (appetite suppressants used in the short term) should not be used in subjects with uncontrolled high blood pressure or a history of heart disease (Apovian et al., 2015).”
Horn, D. B., Linetzky, B., Davies, M. J., Laffin, L. J., Wang, H., Murphy, M. A., Zimner-Rapuch, S., Lau, E., Arad, A. D., & Lee, C. J. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.6112 · Cited by 50
Use of weight loss medications in patients after bariatric surgery.
Redmond, I. P., Shukla, A. P., & Aronne, L. J. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00425-1 · Cited by 50
Self-citationRole of flavonoids in controlling obesity: molecular targets and mechanisms
Mahboob, A., Samuel, S. M., Mohamed, A., Wani, M. Y., Ghorbel, S., Miled, N., Büsselberg, D., & Châari, A. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1177897 · Cited by 71
“Anti-obesity treatment is recommended for individuals with body mass index (BMI) higher than 30 or higher than 25-27 with comorbidities (15, 16).”
BackgroundNaltrexone ER/Bupropion ER: A Review in Obesity Management
Greig, S. L., & Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0427-5 · Cited by 65
Clinical review of subcutaneous semaglutide for obesity
Phillips, A., & Clements, J. N. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13574 · Cited by 49
Current concepts in management of weight regain following bariatric surgery
Shukla, A. P., He, D., Saunders, K. H., Andrew, C., & Aronne, L. J. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1447922 · Cited by 49
Self-citationHamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 96
“They are typically indicated for individuals with a BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity, who have not achieved sufficient weight loss through diet and exercise alone [19].”
BackgroundBaek, J.-H., Kim, N.-J., Song, J., & Chun, K. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.11.031 · Cited by 54
“obesity and increases adaptation to behavioral modification (4).”
BackgroundIs Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?
Conceição-Furber, E., Coskun, T., Sloop, K. W., & Samms, R. J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.868037 · Cited by 48
Naltrexone/bupropion for the Treatment of Obesity and Obesity With Type 2 Diabetes
Apovian, C. M. (2016) · Future Cardiology · doi:10.2217/fca.15.79 · Cited by 47
Self-citationSaad, F., Doros, G. D., Haider, K. S., & Haider, A. (2020) · International Journal of Obesity · doi:10.1038/s41366-019-0517-7 · Cited by 57
Distinguishing emotional from physical activation in ambulatory psychophysiological monitoring
Wilhelm, F. H., Pfaltz, M. C., Grossman, P., & Roth, W. T. (2006) · PubMed · doi:10.5451/unibas-ep9413 · Cited by 48
Effect of Obesogenic Medications on Weight‐Loss Outcomes in a Behavioral Weight‐Management Program
Desalermos, A., Russell, B., Leggett, C., Parnell, A., Ober, K., Hagerich, K., Gerlan, C., Ganji, G., Lee, E., Proudfoot, J. A., et al. (2019) · Obesity · doi:10.1002/oby.22444 · Cited by 47
“The Endocrine Society Clinical Practice Guidelines advise that obesogenic medications should be avoided in patients with overweight and obesity (13).”
BackgroundMethodInfluentialMöllmann, J., Kahles, F., Lebherz, C., Kappel, B. A., Baeck, C., Tacke, F., Werner, C., Federici, M., Marx, N., & Lehrke, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12839 · Cited by 53
“Pharmacological strategies remain challenging because of limited efficacy, rebound phenomena and safety limitations.(3) Bariatric surgery has consequently proven to be the most successful weight loss intervention.”
BackgroundKim, O. Y., Chung, J. Y., & Song, J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104411 · Cited by 43
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
D’Ascanio, A. M., Mullally, J. A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000513 · Cited by 46
Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity
Pressley, H., Cornelio, C. K., & Adams, E. N. (2022) · Journal of Pharmacy Technology · doi:10.1177/87551225221116010 · Cited by 46
Pharmacotherapy in pediatric obesity: current evidence and landscape
Singhal, V., Sella, A. C., & Malhotra, S. (2021) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000587 · Cited by 45
“It reduces the reuptake of norepinephrine (NE) thereby stimulating the pro-opiomelanocortin (POMC) neurons in the hypothalamus [21] and also affects serotonin and dopamine reuptake, which in the prefrontal cortex improves inhibitory control of appetite [22,23] (Fig.”
BackgroundStrategies to reduce attrition in weight loss interventions: A systematic review and meta‐analysis
Pirotta, S., Joham, A., Hochberg, L., Moran, L., Lim, S., Hindle, A., & Brennan, L. (2019) · Obesity Reviews · doi:10.1111/obr.12914 · Cited by 45
“For this reason, they are currently recommended by international obesity guidelines to be included in weight loss interventions, rather than single stand‐alone strategies.(84,98,99) In this review, interventions combined dietary, physical activity, behavioural techniques (eg, self‐monitoring, time management, barrier…”
BackgroundObesity in the Workplace: Impact, Outcomes, and Recommendations
Yarborough, C. M., Brethauer, S. A., Burton, W. N., Fabius, R. J., Hymel, P. A., Kothari, S. N., Kushner, R. F., Morton, J. M., Mueller, K. L., Pronk, N. P., et al. (2018) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000001220 · Cited by 63
“Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity.”
MethodInfluentialGuo, S., Zhao, H., Ma, Z., Zhang, S., Li, M., Zheng, Z., Ren, X., Ho, C., & Bai, N. (2020) · Molecules · doi:10.3390/molecules25174001 · Cited by 47
“Among these options, appropriate diet and lifestyle changes plus moderate exercise are generally considered the most ideal ways to lose weight [10].”
BackgroundAcid–base safety during the course of a very low-calorie-ketogenic diet
Gomez-Arbelaez, D., Crujeiras, A. B., Castro, A. I., Goday, A., Mas-Lorenzo, A., Bellon, A., Tejera, C., Bellido, D., Galban, C., Sajoux, I., et al. (2017) · Endocrine · doi:10.1007/s12020-017-1405-3 · Cited by 44
Srivastava, G., & Buffington, C. K. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3141-z · Cited by 51
Obesity: seize the day, fight the fat
Pοlyzos, S. A., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.12.011 · Cited by 50
Energy balance and obesity in individuals with cystic fibrosis
Litvin, M., Yoon, J. C., Leey, J., Blackman, S. M., & Brennan, A. L. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.08.015 · Cited by 47
Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity
Hwang, J. H., Laiteerapong, N., Huang, E. S., Mozaffarian, D., Fendrick, A. M., & Kim, D. D. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2025.0905 · Cited by 43
Obesity: A Review of Pathogenesis and Management Strategies in Adult
Aktar, N., Qureshi, N. K., & Ferdous, H. S. (2017) · Delta Medical College Journal · doi:10.3329/dmcj.v5i1.31436 · Cited by 64
Integrative analyses of biomarkers and pathways for adipose tissue after bariatric surgery
Liu, Y., Jin, J., Chen, Y., Chen, C., Chen, Z., & Xu, L. (2020) · Adipocyte · doi:10.1080/21623945.2020.1795434 · Cited by 44
“rently shows a limited weight loss effect [6].”
BackgroundJirapinyo, P., Hadefi, A., Thompson, C. C., Patai, Á. V., Pannala, R., Goelder, S. K., Kushnir, V. M., Barthet, M. A., Apovian, C. M., Boškoski, I., et al. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2023.12.004 · Cited by 54
Self-citationSemaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Salvador, R., Moutinho, C. M. S. G., Sousa, C., Vinha, A. F., Carvalho, M. C., & Matos, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18030399 · Cited by 55
Halpern, B., & Mancini, M. C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1247807 · Cited by 41
Pharmacological management of obesity an endocrine society clinical practice guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · Reproductive Endocrinology · doi:10.18370/2309-4117.2015.23.59-63 · Cited by 41
Self-citationPrecision Medicine for Obesity
Cifuentes, L., Hurtado, M. D., Eckel‐Passow, J. E., & Acosta, A. J. (2021) · Digestive Disease Interventions · doi:10.1055/s-0041-1729945 · Cited by 50
Melanocortin‐4 receptor complexity in energy homeostasis,obesity and drug development strategies
Fatima, M. T., Ahmed, I., Fakhro, K. A., & Akil, A. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14618 · Cited by 57
Smith, S. R., Garvey, W. T., Greenway, F. L., Zhou, S., Fain, R., Pilson, R., Fujioka, K., & Aronne, L. J. (2017) · Obesity · doi:10.1002/oby.21811 · Cited by 42
“Lorcaserin is not a sympathomimetic (22).”
Self-citationSzczerbiński, Ł., & Florez, J. C. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00232-2 · Cited by 45
Weight Management in Obstructive Sleep Apnea
Tham, K. W., Lee, P. C., & Lim, C. H. (2019) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2018.10.002 · Cited by 47
Kvitne, K. E., Krogstad, V., Wegler, C., Johnson, L. K., Kringen, M. K., Hovd, M. H., Hertel, J. K., Heijer, M., Sandbu, R., Skovlund, E., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15349 · Cited by 40
“During the initial 3-week LED, the mean 5-OH-omeprazole/ omeprazole ratio (CYP2C19) increased similarly in the RYGB (43% [95% CI 16, 55]) and diet (48% [95% CI 22, 60]) groups (Table 2 and Figure 1E).”
BackgroundJeon, E., Lee, K. Y., & Kim, K.-K. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23032 · Cited by 39
Sutthasupha, P., Promsan, S., Thongnak, L., Pengrattanachot, N., Phengpol, N., Jaruan, O., Jaikumkao, K., Muanprasat, C., Pichyangkura, R., Chatsudthipong, V., et al. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119405 · Cited by 38
Lifestyle-related advice in the management of obesity: A step-wise approach
Chopra, S., Malhotra, A., Ranjan, P., Vikram, N. K., & Singh, N. (2020) · Journal of Education and Health Promotion · doi:10.4103/jehp.jehp_216_20 · Cited by 49
“The last stage is surgical intervention indicated in morbidly obese individuals with BMI >40 kg/m2 or BMI >35 kg/ m2 with multiple obesity‐related complications and compromised quality of life.[10]”
BackgroundUllah, M. I., & Tamanna, S. (2025) · Medicines · doi:10.3390/medicines12030019 · Cited by 38
“Medical conditions such as hypothyroidism, Cushing’s syndrome, and hypothalamic injuries also disrupt energy balance and cause weight gain [38].”
Jeong, H. G., Cho, S., Ryu, K.-J., Kim, T., & Park, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-56818-4 · Cited by 51
“Obesity has become a global epidemic 5,28 .”
BackgroundBiology of Beige Adipocyte and Possible Therapy for Type 2 Diabetes and Obesity
Lizcano, F., & Vargas, D. (2016) · International Journal of Endocrinology · doi:10.1155/2016/9542061 · Cited by 43
Polymeric Carriers for Controlled Drug Delivery in Obesity Treatment
Huang, D., Deng, M., & Kuang, S. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.09.004 · Cited by 41
“As a result, pharmacotherapy is typically considered an adjunctive treatment option [3].”
BackgroundMethodNatural Bioactive Compounds as Potential Browning Agents in White Adipose Tissue
Choi, Y., & Yu, L. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03027-7 · Cited by 41
Claridy, M. D., Czepiel, K. S., Bajaj, S. S., & Stanford, F. C. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.07.021 · Cited by 37
Grabarczyk, T. R. (2018) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2048 · Cited by 37
“Guidelines of organizations such as the American Heart Association (AHA), American College of Cardiology (ACC), The Obesity Society (TOS), and American Association of Clinical Endocrinologists (AACE) have all stated recommendations consistent with product labeling of weight-management medications, typically recommendi…”
Dedov, I. I., Melnichenko, G. A., Troshina, E. A., Mazurina, N. V., & Galieva, M. O. (2018) · Obesity Facts · doi:10.1159/000488880 · Cited by 40
Izaguirre, M., Gil, M. J., Monreal, I., Montecucco, F., Frühbeck, G., & Catalán, V. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0866-3 · Cited by 44
Metadata
- Authors
- Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D.
- Affiliations
- Pennington Biomedical Research Center (US)
- Cornell University (US)
- Denver Health Medical Center (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Geisinger Health System (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-02
- Volume
- 100
- Issue
- 2
- Pages
- 342-362
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2109366467
- Semantic Scholar
- 32e063efbad03793d5b9794138fe9a8f9b3a4650
- Cited by
- 1,347
- References
- 154
- Citations by year
- 2026: 109 · 2025: 128 · 2024: 157 · 2023: 134 · 2022: 112 · 2021: 129 · 2020: 132 · 2019: 98 · 2018: 91 · 2017: 102 · 2016: 95 · 2015: 55
- FWCI
- 82.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, anti-obesity drugs, weight loss, lifestyle modification, obesity-related comorbidities, medication-induced weight gain, drug prescribing, chronic disease medications
- MeSH terms
- Endocrinology, Humans, Obesity, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.